FINWIRES · TerminalLIVE
FINWIRES

Hanmi Pharm Grants Eli Lilly Worldwide License for Intestinal Growth Drug; Shares Rise 6%

By

Hanmi Pharm (KRX:128940) granted Eli Lilly worldwide exclusive rights to develop, produce, and market the South Korean drug company's sonefpeglutide biologic drug candidate, according to a Monday news release in Seoul.

The rights do not cover Korea, according to Hanmi.

Hanmi is set to receive a $75 million upfront payment from the U.S. drug company and an additional $1.19 billion in milestone payments from clinical development, regulatory approval, and commercialization.

The South Korean drug company will also be eligible for royalties following the launch.

Sonefpeglutide is a long-acting glucagon-like peptide 2 or GLP-2 that helps with intestinal growth. GLP-2 obtained approval for short bowel syndrome.

Shares rose 6% during afternoon trading on Monday.

Related Articles

Asia

Azeus Systems' Profit Falls 27% in Fiscal H2

Azeus Systems' (SGX:BBW) profit declined 27% during the fiscal second half ended March 31 to HK$86.4 million from HK$118.1 million a year earlier, according to a Sunday filing with the Singapore Exchange.Shares of the software engineering company were down under 1% in Monday trading.Revenue fell 8% year over year to HK$281.3 million from HK$305.5 million.

$SGX:BBW
Asia

Guangdong Taienkang Pharmaceutical Reports Positive CKBA Cream Trial Results

Guangdong Taienkang Pharmaceutical (SHE:301263) said its Phase IIa clinical trial for CKBA Cream in treating papulopustular rosacea has completed enrollment of all 15 subjects, with positive preliminary data prompting early initiation of Phase IIb.The trial showed significant inflammatory lesion reduction after eight weeks and no serious adverse reactions, according to a Monday filing with the Shenzhen bourse.Shares of the drugmaker rose 1% in recent trade.

$SHE:301263
Asia

Country Garden Seeks Settlements as Litigation, Debt Pressures Mount

Country Garden (HKG:2007) engaged in negotiations with relevant organizations to seek settlements after reporting a net increase of about 1.9 billion yuan in defaulted debt within its consolidated group as of April 30, according to a Friday Hong Kong bourse filing.The increase included defaults arising from overdue principal or interest payments, litigation, non-performance, and cross-default triggers, the company said.Country Garden was newly involved in 11 litigation and arbitration cases with disputed amounts exceeding 50 million yuan each, totaling about 1.5 billion yuan, as of April 30.The developer also recorded three new enforcement actions totaling 1 million yuan during the period.

$HKG:2007